Proactive Investors - Run By Investors For Investors

Sativa Investments signs supply deal with Swiss cannabis oil producer Alponics

The deal follows a supply agreement with a Portuguese cannabis oil firm, announced last month
Alponics will supply Sativa with CBD distillate and isolate

Sativa Investments PLC (LON:SATI) has agreed a commercial offtake agreement with a Swiss supplier of cannabis oil for the manufacture of cannabidiol (CBD) products in the UK.

Under the three-year deal, Switzerland firm Alponics will supply Sativa with CBD distillate and isolate until the end of 2022.  

READ: Sativa Investments inks commercial offtake agreement with Portuguese cannabis oil supplier

Alponics, which was founded by Pacific Rim Plantation Services last year and has operations in Vaud and Valais, is expected to begin production this autumn.

"This commercial agreement with Alponics further advances our smart-sourcing strategy,” said Sativa founder and chief executive, Geremy Thomas.

"We look forward to a long and mutually beneficial relationship with Alan Chaytor and his impressive team."

Last month Sativa decided to abandon a plan to grow its own cannabis produce at a 7.5-acre Wiltshire site.

The company decided sourcing raw material would provide greater returns than growing its own supply.

As part of the new strategy, Sativa announced in late May that it had signed a commercial offtake agreement with Portuguese cannabis oil supplier, MeridianTulip – Empresa Medicinal Lda.

Sativa will acquire low tetrahydrocannabinol (THC) cannabis oil for the UK manufacturer of CBD products at its Somerset headquarters.

THC is a compound in the cannabis plant that gives the “high” associated with recreational use while CBD is non-psychoactive. Medicinal cannabis, which was legalised in the UK late last year, contains CBD and low levels of THC.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full SATI profile View Profile

Sativa Group PLC Timeline

Related Articles

June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
PT exercises
December 20 2018
The Californian company is a bet on an industry that is in need of transformation
cancer cell
The San Diego-based company has developed a patented liquid biopsy technology called Target Selector the detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA)

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use